Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1294739.RAvUkKuOARSLb2FDukJ0kaxj1Es3_z-11a9ghF6cdBz_c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1294739.RAvUkKuOARSLb2FDukJ0kaxj1Es3_z-11a9ghF6cdBz_c130_assertion type Assertion NP1294739.RAvUkKuOARSLb2FDukJ0kaxj1Es3_z-11a9ghF6cdBz_c130_head.
- NP1294739.RAvUkKuOARSLb2FDukJ0kaxj1Es3_z-11a9ghF6cdBz_c130_assertion description "[We investigated prospectively whether treatment with GA leads to clinical and paraclinical changes associated with neuroprotection in patients with relapsing-remitting (RR) MS. Primary aim of this clinical study was to determine serum BDNF levels in RR-MS patients who were started on GA as compared to patients who remained therapy-naive throughout 24 months.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1294739.RAvUkKuOARSLb2FDukJ0kaxj1Es3_z-11a9ghF6cdBz_c130_provenance.
- NP1294739.RAvUkKuOARSLb2FDukJ0kaxj1Es3_z-11a9ghF6cdBz_c130_assertion evidence source_evidence_literature NP1294739.RAvUkKuOARSLb2FDukJ0kaxj1Es3_z-11a9ghF6cdBz_c130_provenance.
- NP1294739.RAvUkKuOARSLb2FDukJ0kaxj1Es3_z-11a9ghF6cdBz_c130_assertion SIO_000772 26439969 NP1294739.RAvUkKuOARSLb2FDukJ0kaxj1Es3_z-11a9ghF6cdBz_c130_provenance.
- NP1294739.RAvUkKuOARSLb2FDukJ0kaxj1Es3_z-11a9ghF6cdBz_c130_assertion wasDerivedFrom befree-2016 NP1294739.RAvUkKuOARSLb2FDukJ0kaxj1Es3_z-11a9ghF6cdBz_c130_provenance.
- NP1294739.RAvUkKuOARSLb2FDukJ0kaxj1Es3_z-11a9ghF6cdBz_c130_assertion wasGeneratedBy ECO_0000203 NP1294739.RAvUkKuOARSLb2FDukJ0kaxj1Es3_z-11a9ghF6cdBz_c130_provenance.